Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Impact of Nirsevimab Prophylaxis on Paediatric Respiratory Syncytial Virus (RSV)-Related Hospitalisations During the Initial 2023/24 Season in Luxembourg
2024
· European Centre for Disease Prevention and Control (ECDC),
· European Centre for Disease Prevention and Control (ECDC),
· Centre Hospitalier de Luxembourg
This study examines the impact of nirsevimab, a new antibody, on reducing RSV-related hospitalizations in Luxembourg during the 2023/24 season. After its introduction, neonatal coverage …
Ask aRCie
Does Nirsevimab Prevent Lower Respiratory Infections Caused by Respiratory Syncytial Virus?
2024
· University of Virginia
This study examines nirsevimab, a monoclonal antibody that helps prevent respiratory syncytial virus (RSV) infections in infants. It found that one injection of nirsevimab significantly …
Outpatient Respiratory Syncytial Virus Infections and Novel Preventive Interventions
2024
· University Medical Center Utrecht,
· Respiratory Syncytial Virus NETwork (ReSViNET) Foundation
This article focuses on respiratory syncytial virus (RSV) infections that occur outside of hospitals. It describes new ways to prevent these infections, which are common …
Rapid Review Showed That Real-World Results on How Nirsevimab Prevented Respiratory Syncytial Virus Hospitalisations Were Similar to Randomised Trials
This brief report describes a study on nirsevimab, a treatment to prevent RSV hospitalizations in infants. Real-world results from studies in Luxembourg, Spain, and the …
Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-Related Outcomes in Hospital and Primary Care Settings: A Retrospective Cohort Study in Infants in Catalonia (Spain)
This study in Catalonia, Spain looks at the effectiveness of nirsevimab, a monoclonal antibody for RSV, in infants under 6 months old. The study shows …
Nirsevimab to Reduce Infant Morbidity From Respiratory Syncytial Virus
This article describes how nirsevimab, a long-acting monoclonal antibody, helps prevent respiratory syncytial virus (RSV) infections in infants. RSV is a common virus that can …
Nirsevimab Brings Breakthrough in the Prevention of Respiratory Syncytial Virus Infection in Infants - Importance of Design
2023
· Capital Medical University
This editorial reviews the clinical studies on nirsevimab and discusses what roles the design has played in the studies. Nirsevimab is a monoclonal antibody that …
Nirsevimab Clinical Guidance and VFC Ordering [Letter]
This letter provides clinical guidance on the use of nirsevimab (Beyfortus), a monoclonal antibody that protects infants and toddlers from respiratory syncytial virus (RSV). Information …
Nirsevimab Updates
This webinar provides updates on nirservimab. Providers will learn about the RSV season in Hawaii, the recommended immunizations for RSV prevention, and best practices for …
Obtaining Beyfortus Through the Vaccines for Children Program
This webpage explains how birthing hospitals can acquire Beyfortus through the Vaccines for Children (VFC) program. Hospitals can get Beyfortus through direct purchase or the …